Intestine-Targeted LNP Development

Intestine-Targeted LNP Development

We develop intestine-targeted LNPs that withstand gastrointestinal conditions, reach defined intestinal segments and cell populations, and deliver functional payloads — supported end to end from lipid design and ligand engineering to enteric formulation, characterization, and in vivo intestinal evaluation.

Intestine-targeted LNPs are engineered to deliver nucleic acids, proteins, and small molecules to the gastrointestinal tract, where conventional LNPs fail on two fronts: systemically administered particles accumulate almost entirely in the liver, and orally administered particles are degraded by gastric acid, bile salts, and luminal enzymes before reaching the epithelium. Intestinal formulations therefore combine gastrointestinal-stability engineering, mucus-compatible surface design, and transporter- or receptor-directed targeting to achieve delivery to enterocytes, M cells, immune cells, or inflammatory-cell populations in specific intestinal segments.

BOC Sciences provides integrated targeted LNP development for intestinal applications, covering ionizable lipid screening, intestinal-cell-targeting ligand synthesis, surface functionalization, payload encapsulation, enteric and microencapsulated format development, and cellular and in vivo evaluation. We support customized LNPs for mRNA, siRNA, ASO, plasmid DNA, genome-editing payloads, and small molecules, with formulation strategies selected according to the target intestinal segment, target cell type, and administration route.

Lipid Nanoparticle Delivery to Intestine DiagramIntestine-Targeted Lipid Nanoparticle Illustration

BOC Sciences Intestine-Targeted LNP Development Services

Our development services integrate lipid chemistry, gastrointestinal-stability engineering, surface targeting, and biological evaluation to address the barriers that limit intestinal delivery. Projects can start with an existing LNP formulation, a candidate targeting ligand, or only a delivery objective defined by intestinal segment and target cell. We customize the development scope according to payload properties, administration route, and the biological readouts that matter most for your program.

Intestine-Selective Lipid Design and Screening

We investigate how ionizable lipid structures and supporting lipid components influence gastrointestinal stability, epithelial interaction, and intestinal-versus-hepatic distribution.

  • Ionizable Lipid Selection: Compare headgroup chemistry, pKa window, tail unsaturation, branching, and ester-versus-amide linker stability to identify candidates suited to luminal exposure and epithelial uptake. Our LNP ionizable lipid optimization services support structure-guided screening.
  • Helper Lipid and Sterol Balance: Adjust phospholipid identity (saturated versus fusogenic helpers), cholesterol content, and lipid ratios to preserve particle integrity in bile-salt-containing media while retaining membrane-fusion capacity.
  • GI-Condition Screening: Rank candidate compositions after incubation in simulated gastric fluid (low pH, pepsin) and simulated intestinal fluid (bile salts, pancreatin), using size, polydispersity, and payload-retention readouts rather than relying on buffer-only stability data.

Intestinal Cell-Targeting Ligand Engineering and Surface Functionalization

We develop ligand-functionalized LNPs to improve interactions with defined intestinal cell populations, including enterocytes, M cells, goblet-cell-associated models, and intestinal macrophages.

  • Transporter-Substrate Ligands: Design bile-acid-derived ligands (cholic, deoxycholic, and taurocholic acid derivatives) as PEG-lipid headgroups to engage apical bile acid transporters expressed on distal small intestinal epithelium.
  • Receptor-Recognition Ligands: Evaluate antibodies, single-domain antibodies, peptides, and carbohydrate-based ligands directed toward accessible epithelial and immune-cell surface markers, with target expression, segment specificity, and species compatibility considered during selection.
  • Conjugation and Surface Display: Optimize linker chemistry, lipid anchors, spacer design, ligand orientation, and display density through our nanoparticle conjugation services, with ligand exposure verified after formulation rather than assumed from feed ratio.

Oral and Local-Delivery LNP Formulation and Process Optimization

We integrate lipid composition, targeting modifications, and payload properties into formulation formats that survive administration and release the payload at the intended intestinal site.

  • Payload Encapsulation: Optimize lipid-to-payload ratios, aqueous and organic phases, formulation pH, and mixing conditions for different payload structures through customized lipid nanoparticle formulation.
  • Gastroprotective Formats: Develop enteric polymer coatings, alginate- or chitosan-based microencapsulation, and lyophilized powder formats that protect LNPs during gastric transit and disperse in the intestinal lumen.
  • Process Parameter Optimization: Refine lipid concentration, flow-rate ratios, purification, and buffer exchange through LNP process optimization, so that targeted particles remain reproducible across formulation batches.

Physicochemical, Gastrointestinal Stability, and In Vivo Evaluation

We evaluate candidate LNPs across particle, barrier, and tissue levels to confirm that gastrointestinal stability and epithelial uptake translate into functional payload delivery in the intestine.

  • Particle Characterization: Analyze particle size, polydispersity index (PDI), zeta potential, morphology, encapsulation efficiency, and payload integrity using appropriate lipid nanoparticle characterization methods.
  • GI Stability and Mucus Interaction: Quantify particle integrity and payload retention after simulated-fluid exposure, and measure mucus diffusion and mucin-binding behavior to distinguish mucus-impenetrable from mucoadhesive surface designs.
  • Epithelial Transport Models: Compare uptake and trans-epithelial transport in intestinal epithelial and co-culture models using nanoparticle cellular uptake testing.
  • Intestinal and Off-Target Distribution: Compare segment-level intestinal accumulation, inflamed-versus-healthy tissue enrichment, and hepatic or splenic exposure through nanoparticle cellular and in vivo evaluation.

Intestine-Targeting Strategies for Lipid Nanoparticles

Intestine-targeted LNPs can be developed through lipid-composition engineering, gastrointestinal-stability optimization, gastroprotective dosage formats, and surface ligand functionalization. BOC Sciences supports lipid design and synthesis, ligand modification, LNP formulation, and delivery evaluation. The following strategies can be applied individually or combined into a multi-layer design.

Strategy 1: Lipid Composition Engineering for Intestinal Tropism

Intestinal accumulation can be pursued by selecting ionizable lipid structures and lipid compositions that favor epithelial interaction and intestinal tissue retention over hepatic uptake. BOC Sciences supports customized ionizable lipid design, synthesis, structural screening, and LNP formulation.

  • Design Approach: Modify ionizable lipid headgroups, pKa, tail unsaturation, and linker chemistry; screen combinations with fusogenic helper lipids, cholesterol, and PEG-lipids for epithelial uptake and intestinal-versus-liver distribution.
  • Use Scenarios: Develop orally or locally administered mRNA-LNPs for intestinal epithelial expression, ASO- and Chemically Modified ASO-Loaded LNPs for intestinal gene silencing, and anti-inflammatory siRNA formulations for colitis research.

Research reference: Reversely engineered LNPs composed of phosphatidic acid, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol (5:2:3) for oral IL-22 mRNA delivery to injured colonic mucosa (~200 nm, −18 mV) (Biomaterials, 2022); novel ionizable-lipid LNPs (L15) that reduced the efficacious dose of anti-TNF-α locked nucleic acid 30-fold in a colitis model (Nature Communications, 2025).

Strategy 2: Formulation Optimization for Gastrointestinal Stability

Orally administered LNPs must remain intact through gastric acid, bile salts, lipases, and luminal nucleases. BOC Sciences supports composition and process optimization to keep particles and payloads stable until they reach the target segment.

  • Design Approach: Tune ionizable lipid pKa and tail saturation for acid and bile-salt resistance, balance PEG-lipid content with PEGylated lipid nanoparticle architectures to limit mucin aggregation while preserving uptake, and screen cryoprotectants for powder formats.
  • Use Scenarios: Develop oral siRNA, mRNA, and small-molecule LNPs that retain encapsulated payload after simulated gastrointestinal exposure, and stabilize targeted LNPs before microencapsulation.

Research reference: Arginine-modified lipid nanoparticles carrying TNF-α siRNA remained structurally intact for 12 hours in simulated digestive fluids with approximately 84.5% payload protection, enabling oral silencing in colitis mice (Chemical Engineering Journal, 2025).

Strategy 3: Enteric Coating and Microencapsulation for Colon-Selective Release

Segment-selective delivery, particularly to the colon, can be achieved by enclosing stable LNPs inside gastroprotective carriers that release only under intestinal conditions. BOC Sciences supports coating and microencapsulation development, release testing, and integrated LNP-microparticle formulation.

  • Design Approach: Apply pH-soluble polymeric coatings or alginate- and chitosan-based microencapsulation, then verify coating integrity in gastric media and release behavior at intestinal pH, supported by pH-responsive lipid nanoparticles and matched release profiling.
  • Use Scenarios: Develop colon-targeted oral siRNA and mRNA formats for inflammatory bowel disease research, and microencapsulated antigen- or cytokine-mRNA LNPs for intestinal immune studies.

Research reference: TNF-α siRNA-loaded LNPs microencapsulated in gastroresistant alginate particles (≥90% encapsulation of both siRNA and LNPs) targeted the inflamed colon and markedly reduced tissue damage in a TNBS-induced colitis model (Drug Delivery and Translational Research, 2025).

Strategy 4: Ligand Functionalization for Intestinal Cell Targeting

Cell-level specificity can be added by displaying transporter substrates, antibodies, single-domain antibodies, or peptides on the LNP surface. BOC Sciences supports ligand selection, synthesis, conjugation chemistry, and functionalized LNP development.

  • Design Approach: Conjugate bile-acid ligands to PEG-lipids for transporter-mediated enterocyte uptake, or display antibodies and single-domain antibodies against accessible epithelial markers using site-selective coupling chemistry, controlling orientation and density through nanoparticle surface functionalization services, including VHH-conjugated lipid nanoparticles.
  • Use Scenarios: Develop mRNA-LNPs for epithelial expression, trans-epithelial delivery formats for mucosal uptake studies, and macrophage-directed siRNA LNPs for intestinal inflammation research.

Research reference: Cholic acid–PEG-lipid modification increased bile-acid-transporter-mediated uptake and protein expression of mRNA-LNPs in differentiated intestinal epithelial cell models (Journal of Nanoparticle Research, 2024); APN-targeted VHH single-domain antibody-functionalized LNPs achieved epithelial uptake and transcytosis across the gut barrier in intestinal organoids and in vivo (Journal of Controlled Release, 2025).

Which Intestine-Targeting Strategy Fits Your LNP Project?

Share your payload, target segment, and administration route. BOC Sciences can help evaluate feasible design options, synthesize relevant components, and develop a comparative formulation strategy.

Supported Payloads for Intestine-Targeted LNPs

BOC Sciences develops intestine-targeted LNPs for the payload classes most frequently used in gastrointestinal delivery research. Each payload requires a matched loading strategy, gastrointestinal-stability approach, and functional readout, and we help connect intestinal-targeting design with payload-specific formulation requirements.

Payload TypeSupported Uses & Intestine-Targeted LNP Development ConsiderationsRequest Information
Intestine-Targeted LNP for mRNADesigned for epithelial and immune-cell expression studies in the gastrointestinal tract, including cytokine and barrier-factor expression. Development focuses on mRNA integrity under luminal conditions, epithelial uptake, and intestinal-versus-hepatic expression ratios, supported by our lipid nanoparticles for mRNA delivery platform.Inquiry
Intestine-Targeted LNP for siRNASuitable for local gene silencing in epithelial and inflammatory-cell populations, including TNF-α and other cytokine-pathway targets. Development evaluates siRNA retention through simulated gastrointestinal exposure, epithelial and macrophage uptake, and inflamed-tissue enrichment.Inquiry
Intestine-Targeted LNP for miRNAApplicable to miRNA replacement and inhibition studies in intestinal epithelium and immune-cell models. Development addresses duplex loading, nuclease protection during luminal transit, and target modulation in intestinal cell panels, drawing on our lipid nanoparticles for miRNA delivery experience.Inquiry
Intestine-Targeted LNP for Antisense OligonucleotidesDesigned for splice-modifying and knockdown oligonucleotide research in intestinal models, where high-dose requirements make delivery efficiency decisive. Development focuses on oligonucleotide loading, epithelial uptake, and dose-sparing behavior, supported by our lipid nanoparticles for ASO delivery services.Inquiry
Intestine-Targeted LNP for circRNA and saRNADesigned for payloads requiring strong protection and sustained expression in the gastrointestinal tract. Development considers payload integrity during luminal exposure, encapsulation behavior, and expression duration in intestinal cell models, supported by our lipid nanoparticles for circRNA delivery platform.Inquiry
Intestine-Targeted LNP for pDNAApplicable to plasmid-based expression research in intestinal epithelial models, where nuclear delivery after epithelial uptake is the limiting step. Development addresses large-payload condensation, particle size control, and epithelial transport, building on our lipid nanoparticles for pDNA delivery capabilities.Inquiry
Intestine-Targeted LNP for Cas9 mRNA and sgRNADesigned for local genome-editing research in intestinal epithelium, where transient Cas9 expression limits prolonged nuclease exposure. We evaluate co-loading of Cas9 mRNA and guide RNA, editing readouts in intestinal cell and organoid models, and particle consistency after gastrointestinal-format processing, drawing on our lipid nanoparticles for CRISPR RNP delivery capabilities.Inquiry
Intestine-Targeted LNP for Protein and PeptideApplicable to enzymes, signaling proteins, and peptide payloads intended for intestinal delivery research, including barrier-protective factors. Formulation work emphasizes protection from proteolysis, mucosal uptake, and preserved biological activity, drawing on our protein encapsulation in LNPs experience.Inquiry
Intestine-Targeted LNP for Small MoleculeDesigned for hydrophobic, amphiphilic, or ionizable small molecules studied in intestinal inflammation, permeability, and metabolism research. We evaluate drug–lipid compatibility, loading method, retention during gastrointestinal transit, and release behavior at the target segment, supported by our lipid nanoparticles for small molecule delivery services.Inquiry
Intestine-Targeted LNP for AntigenSuitable for mucosal immune-priming studies in Peyer's patch and intestinal immune-cell models. Development addresses antigen loading, epithelial and M-cell uptake, and immune-cell delivery after oral administration, supported by our lipid nanoparticles for antigen delivery platform.Inquiry
Intestine-Targeted LNP for Fluorescent and Tracking LabelsSupports labeled particles used to map intestinal segment distribution, mucus and epithelial localization, and inflamed-versus-healthy tissue enrichment, enabled by our tracking-labeled lipid nanoparticles capabilities.Inquiry
Intestine-Targeted LNP for Custom PayloadDeveloped for unusual payloads, co-delivery systems, or early feasibility studies. We evaluate payload compatibility, loading sequence, gastrointestinal-stability approach, targeting modification route, and delivery performance in the agreed intestinal cell models.Inquiry
Need an Intestine-Targeted LNP for Your Specific Payload?

Tell us your payload, target intestinal segment, and delivery route, and BOC Sciences will propose an intestine-targeting strategy that fits your project.

Our Intestine-Targeted LNP Development Workflow

Projects can begin with an existing LNP formulation, a candidate targeting ligand, or only a delivery objective. We organize the work into four practical stages and refine the plan as stability, transport, and biological evidence becomes available.

Project requirement discussion

1Define the Intestinal Segment, Target Cells, Payload, and Delivery Route

We review the payload class, target segment — duodenum, jejunum, ileum, or colon — intended cell population (enterocytes, M cells, goblet-cell-associated models, intestinal macrophages), baseline formulation if available, and desired biological readouts. The administration route — oral, rectal/local, or systemic — is fixed at this stage because it determines the barrier profile the formulation must clear.

Lipid composition and targeting architecture selection

2Select Lipid Composition and Targeting Architecture

We propose candidate ionizable lipids, helper lipid and cholesterol balances, and PEG-lipid architectures, then select the targeting layer — transporter-substrate ligands, receptor-recognition ligands, or composition-driven intestinal preference. Ratios are optimized through structured LNP lipid ratio optimization services, and each design includes matched non-targeted control LNPs.

LNP formulation and characterization

3Formulate and Characterize Candidate LNPs

Candidates are prepared under controlled mixing conditions, including microfluidic LNP production services where compositional screening demands tight reproducibility, and compared for particle size, PDI, zeta potential, ligand density, and payload retention. Gastroprotective formats — enteric coatings or microencapsulation — are applied at this stage when the route requires them, and only candidates meeting agreed particle-attribute thresholds advance.

GI stability and intestinal delivery evaluation

4Evaluate GI Stability, Mucosal Transport, and Functional Delivery

Selected candidates are exposed to sequential simulated gastric and intestinal fluids, then compared for mucus diffusion, epithelial uptake, and trans-epithelial transport with apparent permeability (Papp) readouts in polarized monolayers. Functional endpoints — reporter expression, gene knockdown, or editing outcomes — are measured in intestinal cell and organoid models. In vivo studies combine nanoparticle in vivo distribution analysis with segment-level intestinal quantification and hepatic or splenic off-target measurement. Findings are summarized as a comparative dataset with documented design tradeoffs and suggested next experiments.

What Intestine-Targeted LNP Development Challenges Do We Solve?

An intestine-targeted LNP may be well characterized in buffer yet fail completely after administration — degraded in the lumen, trapped in mucus, taken up by the wrong cells, or cleared by the liver. We investigate formulation and biological factors together and use matched comparison studies to identify the step limiting performance.

Gastrointestinal Degradation and Premature Payload Release

Gastric acid (pH 1–3), bile salts, pancreatic lipases, and luminal nucleases can destabilize particles and strip payloads before they reach the epithelium. We expose every candidate to sequential simulated gastric and intestinal fluids and quantify payload retention at defined time points, then correct the limiting factor — ionizable lipid structure, cholesterol content, surface composition, or the absence of a gastroprotective format — instead of assuming that a stable-in-buffer particle is stable in vivo.

Mucus Entrapment and Limited Epithelial Transport

The mucus layer is a dense, negatively charged hydrogel that immobilizes many cationic or large particles, while mucoadhesive designs trade uptake for retention. We measure mucus diffusion and mucin binding for each surface design, then tune particle size, surface charge, and PEG-lipid density to position each formulation on the retention-versus-penetration spectrum that fits the target segment, verifying the effect in transwell transport rather than uptake-only assays.

Insufficient Target-Cell Uptake and Intracellular Delivery

Gastrointestinal fluid contains little apolipoprotein E, so the uptake pathway that drives conventional intravenous LNP transfection barely operates in the lumen, and polarized epithelium with tight junctions resists particle internalization. We add uptake mechanisms deliberately — transporter-substrate ligands, receptor-recognition single-domain antibodies, or fusogenic helper lipids — and compare intracellular localization with functional readouts, applying LNP endosomal escape evaluation to identify post-uptake limitations before reformulating.

Variable Intestinal Distribution and Off-Target Organ Accumulation

Delivery can differ widely between intestinal segments, between inflamed and healthy tissue, and between luminal retention and systemic absorption into liver and spleen. We use labeled particles and compartment-aware readouts to map where the payload actually accumulates, then adjust coating dissolution behavior, ligand density, and composition to increase inflamed- or segment-specific enrichment relative to off-target organs rather than reporting total signal alone.

Facing GI Degradation or Poor Epithelial Delivery?

Tell us about your current lipid composition, dosage format, payload, and evaluation results. BOC Sciences can help investigate the limiting formulation parameters and establish a focused optimization plan.

Applications of Intestine-Targeted LNPs

Intestine-targeted LNPs open delivery opportunities for nucleic acids, proteins, and small molecules in inflammatory bowel disease, gastrointestinal oncology, mucosal immunity, and epithelial repair research. BOC Sciences supports customized LNP development for these applications, including payload selection, lipid and ligand engineering, gastroprotective format development, and functional delivery evaluation.

01

Inflammatory Bowel Disease and Colitis Research

  • Cytokine mRNA Delivery: Develop LNPs carrying IL-22 or other epithelial-protective cytokine mRNA for local expression in injured colonic mucosa. Orally delivered IL-22 mRNA-LNPs have accelerated mucosal healing in acute colitis models (Biomaterials, 2022).
  • Anti-Inflammatory Oligonucleotide Delivery: Explore siRNA- and Chemically Modified AChemically Modified ASO-Loaded LNPsLoaded LNPs targeting TNF-α and related inflammatory pathways. LNP-delivered anti-TNF-α Antisense Oligonucleotides achieved a 30-fold dose reduction versus unformulated oligonucleotide in a colitis model (Nature Communications, 2025), and microencapsulated TNF-α siRNA-LNPs targeted the inflamed colon after oral administration (Drug Delivery and Translational Research, 2025).
02

Colorectal Cancer and Colitis-Associated Tumorigenesis Research

  • Local Gene Silencing in Tumor Models: Develop siRNA- and miRNA-loaded LNPs directed toward tumor-associated epithelial and myeloid cell populations, using inflammation- and tumor-associated surface markers as ligand-selection anchors.
  • Mucosal Immune Priming: Explore orally delivered antigen- or cytokine-mRNA LNPs for gastrointestinal immune-activation studies, where intestinal dendritic-cell engagement and mesenteric lymph drainage shape the immune outcome.
03

Intestinal Epithelial Barrier Repair and Mucosal Regeneration

  • Barrier-Protective Factor Expression: Develop mRNA-LNPs encoding barrier-repair and epithelial-growth factors for permeability and wound-healing research in injured mucosa models.
  • Trans-Epithelial Delivery Formats: Explore receptor-directed LNPs designed to cross the epithelial barrier, informed by single-domain antibody-functionalized LNPs that achieved epithelial transcytosis in intestinal organoids and in vivo (Journal of Controlled Release, 2025).
04

Local Gene Modulation and Genome-Editing Research

  • Intestinal Gene Editing: Develop LNPs carrying Cas9 mRNA with guide RNA, or base- and prime-editing payloads, for local epithelial editing studies, taking advantage of transient nuclease expression and repeat-dosing capability.
  • Long-Term Modulation: Explore ASO- and circRNA-loaded LNPs for sustained gene modulation in intestinal epithelium, supported by gastrointestinal-stability formats matched to the intended dosing schedule.
Develop an Intestine-Targeted LNP for Your Research Application

Tell us your intended application and development requirements. Drawing on our experience and relevant published research, BOC Sciences can help design, synthesize, formulate, and evaluate intestine-targeted LNPs tailored to your project.

Why Choose BOC Sciences for Intestine-Targeted LNP Development?

Barrier-Focused Intestinal Delivery Design Expertise

We map every formulation decision to a specific gastrointestinal barrier — luminal degradation, mucus entrapment, epithelial uptake, or endosomal escape — so that optimization targets the step actually limiting delivery rather than the easiest variable to change.

Intestine-Specific Ligands and Surface Chemistries

Our workflows cover bile-acid transporter substrates, epithelial receptor-recognition antibodies and single-domain antibodies, M-cell-oriented ligands, and mucus-compatible surface designs, allowing the targeting layer to be matched to the intestinal segment and cell population rather than forced onto a fixed platform.

GI-Stability and Dosage-Format Engineering Capability

Beyond particle formulation, we develop enteric coatings, microencapsulation, and lyophilized powder formats, and verify each format in simulated gastric and intestinal media — connecting dosage-form decisions directly to LNP performance instead of treating them as separate workstreams.

Comprehensive In Vitro and In Vivo Intestinal Evaluation

Simulated-fluid stability, mucus diffusion, epithelial transport, organoid and cell-model functional readouts, and segment-level in vivo distribution are combined in one program, so that formulation changes can be interpreted against both barrier and tissue-level delivery data.

End-to-End Intestine-Targeted LNP Development Services

From lipid synthesis and ligand conjugation to gastroprotective formatting, characterization, and intestinal delivery evaluation, the full development chain is handled within one integrated plan, reducing the disconnect between targeting chemistry and real intestinal performance.

FAQs

How can LNPs maintain integrity during gastrointestinal transit?

Maintaining LNP integrity during gastrointestinal transit requires consideration of gastric acidity, digestive enzymes, bile salts, and changing intestinal conditions. Formulation strategies include optimizing ionizable lipid structures, helper phospholipids, cholesterol content, and PEG-lipid composition to reduce particle disruption and premature payload leakage. Protective excipients or external enteric coatings can provide additional protection when oral delivery is intended. BOC Sciences supports gastrointestinal stability evaluation using simulated gastric and intestinal media, together with particle characterization and payload integrity analysis, helping identify formulations that retain their structural and functional properties before reaching the intended intestinal region.

Intestinal mucus can trap nanoparticles through electrostatic, hydrophobic, and steric interactions with mucin networks. To improve mucus penetration, LNP formulations can be optimized through particle size control, surface charge adjustment, PEG-lipid selection, and surface hydrophilicity modification. However, mucus penetration and mucus adhesion serve different purposes: highly adhesive particles may provide local retention but exhibit limited transport toward epithelial cells. BOC Sciences can compare surface compositions and evaluate particle transport and retention using appropriate mucus models, helping determine whether a formulation is better suited for mucosal penetration, local retention, or subsequent epithelial delivery.

Colon-selective LNP delivery can be explored by combining gastrointestinal protection with region-dependent release mechanisms. External enteric coatings may protect LNPs during gastric transit, while pH-responsive polymers or enzyme-sensitive matrices can be designed to promote release in selected intestinal regions. Microencapsulation provides another approach by incorporating preformed LNPs into protective polymeric structures. The coating or matrix must be evaluated separately from the encapsulated LNP to confirm that particle integrity is preserved after release. BOC Sciences supports formulation development, coating optimization, release characterization, and intestinal distribution evaluation for colon-oriented delivery research.

Yes. Intestinal macrophage targeting can be investigated through ligand-functionalized LNPs that recognize accessible receptors on selected macrophage populations. Carbohydrate-based ligands, including appropriately designed galactose-containing structures, can be explored according to receptor expression and recognition mechanisms. Peptides and other receptor-binding components may also be considered when suitable targets are identified. Successful targeting requires more than increased particle association; receptor accessibility, cellular internalization, intracellular payload release, and functional gene modulation should all be evaluated. BOC Sciences supports ligand synthesis, lipid-anchor conjugation, surface-density optimization, and macrophage-associated cellular delivery studies.

Intestinal LNP evaluation should combine physicochemical characterization, gastrointestinal stability testing, cellular studies, and tissue-level analysis. Particle size, PDI, zeta potential, morphology, encapsulation efficiency, and payload integrity establish the initial formulation profile. Simulated gastric and intestinal media can assess particle stability, while mucus models help investigate transport and retention. Intestinal epithelial and macrophage models can be used to examine cellular uptake and functional payload activity through reporter expression or target-gene modulation. For studies, tissue imaging, intestinal segment analysis, and organ distribution measurements help distinguish local accumulation from productive cellular delivery.

* Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Online Inquiry
Verification code